Exclusive: Autonomize AI gets $28M for health agents
Autonomize AI, a provider of AI agents to health systems and plans, raised $28 million in Series A funding, CEO Ganesh Padmanabhan tells Axios exclusively.
The big picture: It's the latest sign of investor appetite for infrastructure-layer AI in health care — especially platforms that promise scale, compliance, and a clear ROI.
Follow the money: Autonomize plans to expand deployment of its "Copilot" AI agents across payers, providers, and life sciences organizations.
Valtruis, Cigna Ventures, and Tau Ventures led the round, joined by previous investors Asset Management Ventures, ATX Venture Partners, and Capital Factory.
The Series A provides 24-month runway, though the company could raise before then, Padmanabhan says.
How it works: Austin-based Autonomize's agentic AI platform stitches together pre-trained agents for tasks like benefits verification, care planning, and chart review.
The company uses a human-in-the-loop model and offers explainability and compliance features — two key factors for success in health care.
Most of its customers are payors, followed by value-based care providers and syndicated health plans.
Between the lines: Autonomize was built specifically for the highly regulated business of health care, per Padmanabhan.
"I've met nurses who have a 400-page binder on their desk that they still refer to before making adjudication decisions within health plans," says Padmanabhan. "There's no way an AI agent is going to find that because that data, that knowledge, is not digitized."
What they're saying: "The way the technology is configured is, you set up an agent for a particular use case and it's reusable for others," says Valtruis managing director Mike Spadafore.
"A lot of these workflows are made up of 15, 20 different steps that you assemble into different workflows," Spadafore adds, noting Autonomize's repeatability was attractive.
"A complex workflow, like care management or like prior authorization, is actually multiple sub workflows," Padmanabhan says. A benefit check is one example —where users are looking at patient information across multiple documents.
Reality check: The market is flooded with "AI for health care" startups, but most are still struggling to show meaningful, repeatable results.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
Most people are guilty of doing this in the shower — but experts warn it's incredibly dangerous: ‘Don't do it'
What you do in the shower is your business, but the one thing experts are warning you to stop doing while sudsing up: peeing. One healthcare expert shared in a now-viral TikTok with over 1 million views that emptying your bladder while standing in the shower can be damaging — especially for women. Advertisement 'Hot take but don't pee standing up in the shower or anywhere for that matter. Ladies, you are training your bladder that it's okay to empty while standing. Don't do it! This could cause bladder leakage,' @kingsley.502 wrote as her caption. As expected, people ran to the comment section to share their opinions on this advice. 'My body created a human… I'm gonna let her tinkle wherever she likes,' one commenter wrote. Advertisement 'I can't even enjoy the simple pleasures in life,' shared another frustrated person. 'Meanwhile sitting for too long messes with our pelvic floor. So what actually is ok anymore?' said someone else, making a valid point. Many people in the comments of the viral TikTok video were upset to learn of this news. uduhunt – It's no surprise that this news is upsetting for many, considering almost a quarter of Americans admit to peeing in the shower regularly, according to a survey. Advertisement Unfortunately for these multitasking people, @kingsley.502 wasn't far off with her opinion on shower peeing — as other experts backed up her claims. 'It is one, not very hygienic, but more important than that, it will destroy your pelvic floor, and also it might create mental associations where you hear water running and all of a sudden you need to run to the bathroom,' Houston-based OB-GYN Emma Qureshey explained in a TikTok. And standing while peeing is not only unhealthy for women — it's also dangerous for men. Advertisement Since the pelvis and spine muscles are most relaxed when sitting, Gerald Collins, a consultant urological surgeon at Alexandra Hospital in Cheshire, England, said that 'Sitting is probably the most efficient way of doing it [peeing]' the doctor explained, Standing while urinating also puts men at risk for benign prostatic hyperplasia — which occurs when the prostate gland and surrounding tissue expand, obstructing the urethra. Sadly, for many men, the thought of sitting while peeing is looked down upon. In Germany, those who don't stand to relieve themselves are called 'Sitzpinkler' — a slur implying they are 'wimpy or effeminate.'
Business Upturn
an hour ago
- Business Upturn
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]
Hypebeast
2 hours ago
- Hypebeast
HAVEN's Summer 2025 Collection Centers on the Pacific Northwest's Terrain
Vancouver-based labelHAVENhas unveiled a coastal campaign for its Summer 2025 collection, returning with a capsule of essentials designed for the warm days and cool nights of Summer in the Pacific Northwest. Utilizing cotton-linen gabardines, Japan denim, and lightweight Super 140s wool, the label offers a range of core garments characterized by the label's functional, minimalist ethos. HAVEN opts for a light and neutral color palette inspired by the woodland coast of Vancouver, led by tones of beige, sage green, brown, off-white, and indigo. The collection is anchored by matching linen gabardine sets, comprising a work jacket that reinterprets the classic military BDU (battle dress uniform) garments. Offered in a dark brown and beige colorway, the jacket's ergonomic tailoring and underarm gussets elevate the utilitarian design with contemporary elegance. In indigo and white, Japanese linen denim shirts and trousers offer a cooling feel and soft hand. The denim Helix Pant features twisted side seams for a sculpted fit and added mobility, and functional details, like slant hand pockets, storm welt back pockets, and snap-adjustable waist tabs. HAVEN tops the collection off with wool Summer shirting, including wool versions of the aforementioned denim shirts in beige, green, and brown checks. Utilizing Super 140s wool, known for its ultra-fine quality, the collection also offers short-sleeve camp collar shirts in the same three colorways. See the gallery above for a closer look at the campaign. HAVEN's Summer 2025 Delivery 1 is out now at the brand'swebsiteand physical store.
